Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

Company Overview

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $1.13 to $1.30
• 50-Day Range: $1.12 to $1.49
• 52-Week Range: $1.08 to $16.00
• Volume: 127,221 shs
• Average Volume: 384,406 shs
• Market Capitalization: $3.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Sonnet BioTherapeutics Stock Analysis - MarketRank™

Sonnet BioTherapeutics scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sonnet BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Sonnet BioTherapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.13% of the float of Sonnet BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonnet BioTherapeutics has recently decreased by 21.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sonnet BioTherapeutics does not currently pay a dividend.

Dividend Growth

Sonnet BioTherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.13% of the float of Sonnet BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonnet BioTherapeutics has recently decreased by 21.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sonnet BioTherapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for SONN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Sonnet BioTherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.00% of the stock of Sonnet BioTherapeutics is held by insiders.

Percentage Held by Institutions

Only 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.

SONN Stock Analysis - Frequently Asked Questions

How have SONN shares performed this year?

Sonnet BioTherapeutics' stock was trading at $1.46 at the beginning of 2025. Since then, SONN stock has decreased by 14.4% and is now trading at $1.25.
View the best growth stocks for 2025 here.

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its earnings results on Tuesday, May, 13th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.03.

When did Sonnet BioTherapeutics' stock split?

Sonnet BioTherapeutics's stock reverse split on the morning of Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Sonnet BioTherapeutics' major shareholders?

Top institutional investors of Sonnet BioTherapeutics include MMCAP International Inc. SPC (4.36%). Insiders that own company stock include Pankaj Mohan, Susan Dexter, Nailesh Bhatt and Albert D Dyrness.
View institutional ownership trends.

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Plug Power (PLUG), SNDL (SNDL), NIO (NIO), Zomedica (ZOM), VYNE Therapeutics (VYNE), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/07/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SONN
• CIK: 1106838
• Web: www.chanticleerholdings.com
• Phone: 609-375-2227
• Fax: 704-366-2463
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +1,500.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.44 million
• Net Margins: N/A
• Pretax Margin: -927.00%
• Return on Equity: -408.93%
• Return on Assets: -174.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 3.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.32 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 3,166,000
• Free Float: 3,005,000
• Market Cap: $3.96 million
• Optionable: Not Optionable
• Beta: 0.95